Research and Development

Aging is a natural part and the “last mile” of human development program. We pioneer ways to understand, measure and, ultimately, control its progression. We view aging as a dynamic process and employ big data from biobanks and large medical studies. The combination of analytical approaches originating from the dynamical systems theory and physics of complex systems yields predictive models of aging for biomarkers of aging discovery. Ultimately, the GERO-dynamics principles can be used to suggest and efficiently test state-of-art therapies aimed at the aging process itself.

The recent explosion in popularity of web-connected wearable devices has generated massive amounts of high quality measurements, including physical activity tracks, heart rate, and skin temperature. Over 400M of such devices will be sold in 2020. This creates an unprecedented opportunity for aging research.

Our modeling platform allowed us to perform a systematic evaluation of the relationship between physical activity and biological age, mortality risk, and frailty. To do that, we used human physical activity records from the 2003-2006 National Health and Nutrition Examination Survey (NHANES) and UK BioBank (UKB) databases. These large databases contain uniformly collected digital activity records provided by wearable monitors as well as health and lifestyle information, and death registry.

We proved that it is possible to assess biological age and predict health outcomes based solely on the physical activity data.

Our ready-to-use digital biomarker technology is available for licensing and can be used by life insurance & pension companies to:

  • Develop new generation of personalised underwriting models that will gather all required data from widely available consumer devices.
  • Complement the classical actuarial mortality and morbidity analysis by adding personalised risk factors based on health data.
  • Enhance customer experience and awareness by development of rewards program to cultivate healthy lifestyle choices, resulting in reduced healthcare expenses.

Ongoing pilots:

  • to be announced
  • to be announced

We offer flexible implementation from API to black box or algorithm licensing and create tailored pilot design. Our broader digital biomarker technology includes the analysis of blood, genetics and other biodata and can be used to assess life-extending potential of a drug in longevity clinical trials. We have also created a prototype Gero Healthspan app predicting healthy life expectancy from smartphone data. Contact us to learn more.